Human Umbilical Cord Blood Derived NK cells

The human umbilical cord blood derived NK cells are a kind of immune cells, obtained from the enriched fraction of progenitor cells derived from umbilical cord blood. The cells are the potent allogeneic population, which are used as a promising immunotherapeutic approach for the treatment of cancer, infections and immune disorders. The UCB derived NK cells can be obtained and expanded from an enriched fraction of mononuclear cells, using a cocktail of growth factors, cytokines and feeder cells. The resulting NK cells product is a mixture of mature and trained NK cells with the ability to recognize cancerous as well as infected cells. The UCB derived NK cells are more advantageous as compared to other sources like peripheral blood, bone marrow etc. The availability of NK cells per unit of blood is higher with a less risk of transmission and lower incidence of graft-versus-host diseases (GVHD). The UCB-derived NK cells product can be administered to the patient via infusion and/or injection. The isolation method of NK cells may vary depending upon the experimental requirements and expertise. Kosheeka separates NK cells using magnetic beads like CD56, CD16 as well as NKG2D. The bead bound cells can be separated from the rest of the cells using a magnetic field. The cells isolated with this method are highly purified and enriched for the CD56 population. We recommend transportation of these cells either in fresh as well as cryopreserved form. While fresh NK cells are transported in specialized transport containers at room temperature and protect them from physical shock; the cryopreserved NK cells are shipped in dry ice.

Human Umbilical Cord Blood Derived Mononuclear cells

The human umbilical cord blood derived mononuclear cells is a pure population of precursor cells, isolated from cord blood, shortly after birth. The population contains a mixture of progenitors including lymphocytes, monocytes and stem cells, and are widely studied for their therapeutic potential and immune regulation properties. The cryopreserved as well as fresh batch of mononuclear cells is isolated from cord blood via density gradient separation technique. We are separating with a single spin kit to separate erythrocytes and granulocytes further producing a more stable product. Kosheeka supplies a pool of mononuclear fraction from cord blood both in fresh isolation as well as in cryopreserved format, depending upon the requirements. The product can also be customized depending upon the study parameters like single donor, pooled, with variable cell count per vial. It is also possible to culture and expand these cells further to obtain a choice of cells like mesenchymal stem cells or lymphocytes etc. depending upon the study requirements. The pure population of mononuclear cells have been shown to have various therapeutic applications, including the treatment of autoimmune diseases, like multiple sclerosis, rheumatoid arthritis etc, along with tissue repair and regeneration. Thus, upon demand Kosheeka is able to supply pure population of freshly isolated mononuclear cells from umbilical cord blood in a suspended form in HBSS with 5mM EDTA and 0.5% BSA. The characterization of cord blood derived mononuclear cells is important to understand their potency, cellular composition as well as functional properties. With the help of various advanced techniques like viability analysis, flow cytometry, complete blood count etc. the researchers can gain a comprehensive understanding of mononuclear population and tailor their use for specific applications.